POEMs

Patient-Oriented Evidence That Matters

Some Drugs Slightly Improve Cognition in People with Dementia; Effects on Behavioral or Psychological Symptoms Remain Unclear

 

Am Fam Physician. 2020 Dec 1;102(11):694.

Clinical Question

Can drug treatments improve outcomes in people with dementia?

Bottom Line

Some treatments can improve cognition on research scales, but daily function will not be affected in a noticeable way. Managing behavioral or psychological issues with medication is not supported by current evidence. (Level of Evidence = 1a)

Synopsis

The authors searched four databases, including the Cochrane Library, a clinical trials database, and bibliographies of other systematic reviews, to identify all English-language studies of drug treatments for cognition, function, or behavioral and psychological symptoms associated with Alzheimer-type dementia. Two authors screened possible articles for inclusion. One author performed data extraction, which was verified by a second author. The authors assessed risk of bias and only analyzed results from studies with low or medium risk, removing 97 of the 163 unique studies they identified. The researchers found a small improvement in cognition (standardized mean difference = 0.30) with a low strength of evidence for cholinesterase inhibitors, although there was no effect on overall function or global clinical impression. The most frequently studied cholinesterase inhibitor was donepezil (Aricept). In patients with moderate to severe disease, adding memantine (Namenda) to a cholinesterase inhibitor improved cognition and overall clinical impression, but not function compared with placebo. No treatments had sufficient evidence of their benefit on behavioral or psychological symptoms. Withdrawal from treatment because of adverse effects was higher with cholinesterase inhibitors galantamine (Razadyne) and rivastigmine (Exelon) compared with placebo. There was not significant heterogeneity among the studies. The likelihood of publication bias was not reported.

Study design: Meta-analysis (randomized controlled trials)

Funding source: Government

Setting: Various (meta-analysis)

Reference: Fink HA, Linskens EJ, MacDonald R,

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, editor-in-chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.

 

 

Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Jul 2021

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article